Phase 3RecruitingPriority 1 · Highest priorityNCT07414758
Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy
Plain-language summary
This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
golidocitinib (DRUG): Eligible patients were randomized to receive golidocitinib medicine orally at a planned dose of 150 mg once every other day. | Placebo (DRUG): Eligible patients were randomized to receive placebo orally at a planned dose of 150 mg once every other day.
- Drugs / treatments
- golidocitinib, Placebo
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details